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Neurons aremetabolically protected against degeneration using low-level methylene blue and near-
infrared light interventions. Both of these novel interventions act by a cellular mechanism involving
enhancement of the electron transport chain in mitochondria, which promotes energy metabolism
and neuronal survival (Gonzalez-Lima et al., 2014). Methylene blue preferentially enters neuronal
mitochondria after systemic administration, and at low-doses forms an electron cycling redox
complex that donates electrons to the mitochondrial electron transport chain. Low-level near-
infrared light applied transcranially delivers photons to cortical neurons that are accepted by
cytochrome oxidase, which causes increased cell respiration and cerebral blood flow. Breakthrough
in vivo studies with these interventions suggest that targeting mitochondrial respiration may be
beneficial for protection against different types of neurodegenerative disorders.
The purpose of this paper is to provide an update on the cellular mechanisms mediating the
neuroprotective effects of low doses of methylene blue and near-infrared light, and to argue that the
neurotherapeutic benefits of these two different interventions share the same cellular mechanism
of action based on stimulation of mitochondrial respiration. Presented first is the explanation of the
biochemical redox action of low-dosemethylene as an electron cycler on themitochondrial electron
transport. Presented second is the explanation of the biophysical action of near-infrared light as a
photon donor to cytochrome oxidase that also serves to stimulate mitochondrial electron transport.
We finish with a comparison of these two interventions and how they share a common cellular
mechanism with similar properties such as energy transfer, low-dose hormetic dose-responses, and
enhanced capacity for oxidative metabolic energy production, which serve to protect nervous tissue
from degeneration.
Methylene Blue as Electron Donor
Low-dose methylene blue stimulates mitochondrial respiration by donating electrons to the
electron transport chain. This is possible by a unique auto oxidizing redox chemical property.
Methylene blue is unique among chemicals for several important reasons. Foremost is the
auto oxidizing property that allows methylene blue at low concentrations to form a redox
equilibrium by cycling electrons (i.e., serving as both an electron donor and acceptor). This
property permits the cycling of electrons from chemicals inside the mitochondrial matrix
to electron transport proteins in mitochondria. These transport proteins act as acceptors
for electrons donated by methylene blue in mitochondria. The final acceptor of electrons
in the respiratory chain is oxygen, which is obtained from oxyhemoglobin transported in
the circulation. Molecular oxygen becomes reduced to water in a reaction catalyzed by the
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mitochondrial enzyme cytochrome oxidase (Complex IV,
cytochrome c oxidase). The electron transport chain is coupled
with the biochemical process of oxidative phosphorylation,
which leads to increased oxygen consumption and the formation
of ATP from ADP (Figure 1). Under normal physiological
conditions the electrons that enter the electron transport chain
come from electron donor molecules such as NADH and
FADH2. These molecules derive from the Krebs cycle conversion
of the food we eat. Methylene blue at low concentrations serves
as another source of electrons for the electron transport chain
that is part of mitochondrial respiration, leading to increased
cytochrome oxidase activity and oxygen consumption (Riha
et al., 2005; Wen et al., 2011; Rojas et al., 2012a; Rodriguez et al.,
2014).
In addition, recent functional magnetic resonance imaging
(fMRI) studies show that systemically administered low-
dose methylene blue can directly reduce oxygen to water
and support cerebral metabolic rate of oxygen consumption
and metabolic energy production in normoxic and hypoxic
conditions in vivo (Huang et al., 2013). Since rapid activation
of oxygen consumption leads to a local transient hypoxia,
cytochrome oxidase changes from reducing oxygen to catalyzing
the formation of nitric oxide (Poyton and Ball, 2011). This
in turns leads to a hemodymamic vasodilation response
that increases cerebral blood flow and brain glucose uptake
in vivo (Lin et al., 2012). This metabolic cascade promotes
bigenomic regulation of mitochondrial and nuclear genes whose
expression up-regulate cytochrome oxidase protein subunits and
holoenzyme levels in nervous tissue (Rojas et al., 2012a).
FIGURE 1 | Two neuroprotective interventions for enhancing
mitochondrial respiration. Low-dose methylene blue (MB) acts as an
exogenous electron (e-) cycler, boosting oxygen consumption and cell
respiration (molecular O2 reduced to H2O). Low-level red-to-near-infrared light
directly energizes cytochrome oxidase (Complex IV) via photon absorption,
facilitating its catalytic activity and leading to up-regulation of cytochrome
oxidase levels. These interventions result in long-term increases in the amount
of cytochrome oxidase in the electron transport chain by a process of
enzymatic induction, which promotes oxidative energy metabolism and
neuronal survival. Abbreviations: I–IV, refer to the four electron transport
enzymatic complexes in the inner membrane of mitochondria; MB, is oxidized
methylene blue (blue color); MBH2, is reduced methylene blue (colorless); H
+,
stands for the protons pumped by Complexes I, III, and IV that enter the
mitochondrial matrix via ATP synthase, which results in ATP production.
Near-infrared Light as Photon Donor
Near-infrared light from low-power lasers and light-emitting
diodes (LEDs) stimulates mitochondrial respiration by donating
photons that are absorbed by cytochrome oxidase, a bioenergetics
process called photoneuromodulation in nervous tissue (Rojas
and Gonzalez-Lima, 2013). Photons are packets of luminous
energy from electromagnetic waves. The amount of energy
delivered by a photon depends on the light wave frequency.
Photons in the red-to-near-infrared frequency range of
approximately 620–1150 nm penetrate to the brain and intersect
with the absorption spectrum of cytochrome oxidase (Rojas
and Gonzalez-Lima, 2011). The absorption of luminous energy
by the enzyme results in increased brain cytochrome oxidase
enzymatic activity and oxygen consumption (Rojas et al., 2012b).
Since the enzymatic reaction catalyzed by cytochrome oxidase
is the reduction of oxygen to water, acceleration of cytochrome
oxidase catalytic activity directly causes an increase in cellular
oxygen consumption. Because increased oxygen consumption
by nerve cells is coupled to oxidative phosphorylation, ATP
production increases as a consequence of the metabolic action
of near-infrared light. This type of luminous energy can enter
brain mitochondria transcranially, and—independently of
the electrons derived from food substrates—it can directly
photostimulate cytochrome oxidase activity.
Red-to-near-infrared light not only stimulates mitochondrial
respiration and brain oxygen consumption when light is on. Light
also has a longer lasting effect on metabolic capacity because
its acceleration of cytochrome oxidase activity causes enzymatic
induction, a process dependent on gene expression and protein
synthesis that up-regulates the levels of cytochrome oxidase
(Hayworth et al., 2010). For example, 1 day after a single session
of photoneuromodulation, there are significantly higher levels of
cytochrome oxidase enzyme in the rat brain (Rojas et al., 2012b).
Indeed, behavioral effects in humans can still be observed at 2 and
4 weeks after a single transcranial near-infrared light treatment
(Barrett and Gonzalez-Lima, 2013). This enzymatic induction
provides a long-tern mechanism for increasing the oxidative
metabolic capacity of neurons, which is manifested in vivo by
increases in cerebral rates of oxygen consumption and blood flow
to the brain (Uozumi et al., 2010; Rojas et al., 2012b).
Cellular Mechanisms of Neuroprotection
While low-dose methylene blue and low-level near-infrared
light may produce different pleiotropic cellular effects, both
interventions cause a similar up-regulation of mitochondrial
respiration with similar benefits to protect nerve cells against
degeneration. First, both interventions increase the expression of
brain cytochrome oxidase in vivo (Gonzalez-Lima et al., 2014).
Methylene blue accomplishes this by supporting the electron
transport chain, while near-infrared light does it by directly
energizing cytochrome oxidase via photon absorption (Figure 1).
Still, their primary cellular mechanism of action is the same:
enhancement of mitochondrial respiration.
Second, both interventions share high bioavailability.
Methylene blue readily crosses the blood-brain barrier, builds
Frontiers in Cellular Neuroscience | www.frontiersin.org 2 May 2015 | Volume 9 | Article 179
Gonzalez-Lima and Auchter Neuroprotection by enhancing mitochondrial respiration
up inside neurons, and resides inside respiring mitochondria.
Indeed, methylene blue injected to live animals was first used as
a supravital stain of nervous tissue by Paul Ehrlich and Ramon
y Cajal in the 1890s. In the modern case of near-infrared lasers
used transcranially, the degree of penetration increases with
longer wavelengths and pulse durations within the effective
near-infrared spectrum range. For example, approximately
8–10% of luminous energy reaches the rat cerebral cortex and
1.7–2% reaches the human cerebral cortex (Gonzalez-Lima and
Barrett, 2014).
Third, similar conditions affect their neural effects, such as
the redox and activational status of the target tissue and the
dose-response. Hormesis has been documented for the dose-
responses of both methylene blue (Bruchey and Gonzalez-
Lima, 2008) and near-infrared light (Huang et al., 2011). This
phenomenon means that low doses produce opposite effects
than high doses, and that intermediate doses may be ineffective.
For example, while low doses of methylene blue are used to
treat methemoglobinimia, high doses cause methemoglobinimia
(Bruchey and Gonzalez-Lima, 2008). Hence it does not make
sense to refer to methylene blue without specifying the dose
level, as different doses produce opposite effects. For example,
while high doses may inhibit tau aggregation and nitric oxide
formation in vitro, they are toxic in vivo (Riha et al., 2005; O’Leary
et al., 2010). But systemic low-doses (0.5–4mg/kg) of methylene
blue that stimulate mitochondrial respiration in vivo are safe
and effective in both animals and humans (Rojas et al., 2012a).
Similarly, only low-level near-infrared light is beneficial because
higher doses become ineffective or produce opposite effects. The
dosing for transcranial near-infrared light depends on multiple
parameters besides wavelength, such as transmission, fluency,
irradiance, number of fractions, pulsing, etc. (Huang et al., 2011).
For example, forehead transcranial stimulation of the human
cerebral cortex has been done effectively with a continuous wave
1064 nm laser at 60 J/cm2 (fluence), 250mW/cm2 (irradiance)
for 4min, which corresponds to about 1.2 J/cm2 energy density
reaching the cortical surface with a 2% transmission (Barrett and
Gonzalez-Lima, 2013).
An effective mechanism of stimulation of mitochondrial
respiration protects against neurodegeneration by increasing the
oxidative metabolic energy capacity of neurons and reducing
oxidative damage (Wen et al., 2011). With increases in the
capacity to produce ATP by up-regulation of cytochrome
oxidase, multiple secondary benefits accrue such as enhancement
of neuronal metabolic energy and bigenomic responses,
antiapoptotic signaling, DNA repair, mitogenic signaling, axonal
sprouting, synaptogenesis and brain-derived neurotrophic factor
(Martijn and Wiklund, 2010; Gomes et al., 2012; Poteet et al.,
2012; Rojas and Gonzalez-Lima, 2013; Xuan et al., 2014). Low-
doses of methylene blue and near-infrared light that up-regulate
mitochondrial respiration in vivo have similar neuroprotective
effects in multiple model systems featuring neurodegeneration.
These include models of neurotoxicity (Zhang et al., 2006; Rojas
et al., 2008, 2009a), ischemia (Yip et al., 2011; Watts et al.,
2013; Auchter et al., 2014; Rodriguez et al., 2014), neurotrauma
(Bittner et al., 2012; Oron et al., 2012; Quirk et al., 2012; Shen
et al., 2013; Xuan et al., 2013; Zhang et al., 2014), neurocognitive
and emotional impairment (Callaway et al., 2004; Gonzalez-Lima
and Bruchey, 2004; Wrubel et al., 2007a,b; Riha et al., 2011),
Alzheimer’s disease (Callaway et al., 2002; Auchter et al., 2014),
and Parkinson’s disease (Rojas et al., 2009b; Wen et al., 2011).
Although most of the mechanistic studies have been
undertaken in animal models, the in vivo neuroprotective
benefits of low-dose methylene blue and near-infrared light
have been documented in humans as well (Rojas et al.,
2012a; Rojas and Gonzalez-Lima, 2013). For example, low-
dose methylene blue in humans leads to neuroprotection and
reversal of ifosfamide-induced encephalopathy (Turner et al.,
2003), and it also improves treatment of bipolar and unipolar
depressive disorders (Naylor et al., 1986, 1987). In addition,
a recent controlled, randomized, double-blind study in phobic
patients provided the first peer-reviewed report of improvement
in human memory functions by low-dose methylene blue,
specifically fear extinction memory and contextual memory
(Telch et al., 2014). These human studies suggest that
low-dose methylene blue may have potential therapeutic
applications in neurology as a neuroprotective agent, and in
psychiatry and clinical psychology to facilitate psychotherapeutic
interventions. Similarly, low-level near-infrared light improved
human neurological outcome after ischemic stroke (Lampl et al.,
2007), and enhanced emotional and neurocognitive functions
such as sustained attention and working memory in humans
(Gonzalez-Lima and Barrett, 2014).
Conclusion
We have described two very different chemical-physical
interventions resulting in a similar cellular mechanism targeting
mitochondrial respiration (Gonzalez-Lima et al., 2014). One
entails fostering electron cycling by an auto-oxidizing redox
chemical, and the other using photon absorption from near-
infrared light. New in vivo evidence from animal models and
human studies suggest that low-dose methylene blue and
low-level near-infrared light share a common mechanism of
enhancement of mitochondrial respiration that protects against
neuronal degeneration in a broad range of animal models and
human neurobehavioral disorders. We hope that this fascinating
neuroprotective approach targeting mitochondrial respiration
will stimulate more human studies of potential therapeutic
applications in neurology and psychiatry.
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